Quick answers
- What is Lactic acid, l-, citric acid monohydrate, and potassium bitartrate used for?
- The FDA-approved label (Phexx, Evofem, Inc., May 2, 2025) says: “PHEXX is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. PHEXX is a combination of lactic acid, citric acid, and potassium bitartrate indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Limitations of Use …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Lactic acid, l-, citric acid monohydrate, and potassium bitartrate?
- The “Adverse Reactions” section of the FDA label (Phexx, Evofem, Inc., May 2, 2025) begins: “The following clinically significant adverse reactions are described elsewhere in the labeling: Cystitis and Pyelonephritis [see Warnings and Precautions (5.1)] Most common adverse reactions (≥2%) were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Lactic acid, l-, citric acid monohydrate, and potassium bitartrate have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Lactic acid, l-, citric acid monohydrate, and potassium bitartrate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Lactic acid, l-, citric acid monohydrate, and potassium bitartrate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Lactic acid, l-, citric acid monohydrate, and potassium bitartrate?
- 1 company lists prescription products of Lactic acid, l-, citric acid monohydrate, and potassium bitartrate in the FDA NDC Directory, including Evofem, Inc.
What Lactic acid, l-, citric acid monohydrate, and potassium bitartrate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
PHEXX is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. PHEXX is a combination of lactic acid, citric acid, and potassium bitartrate indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Limitations of Use …
— FDA label: Phexx, Evofem, Inc., effective May 2, 2025. Read the full label on DailyMed →
Label quoted: the one for the most common form (gel, vaginal), Phexx, Evofem, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Lactic acid, l-, citric acid monohydrate, and potassium bitartrate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following clinically significant adverse reactions are described elsewhere in the labeling: Cystitis and Pyelonephritis [see Warnings and Precautions (5.1)] Most common adverse reactions (≥2%) were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain.
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of PHEXX (pre-filled applicator with 5-gram dose) has been evaluated in two clinical trials (Study 1 and Study 2) in 2804 subjects (over 19,000 cycles of exposure). The racial/ethnic distribution was 66% White, 27% Black or African American, 2% Asian, 1% American Indian or Alaska Native, 0.3% Native Hawaiian or Pacific Islander, and 5% other; 32% of the study population was Hispanic. Study 1 included a one-year extension phase where 342 U.S. subjects were exposed to PHEXX for 13 cycles. Hypersensitivity Reaction Of the 2804 PHEXX-treated subjects in Studies 1 and 2, one subject reported a suspected drug hypersensitivity. Avoid PHEXX use in females of reproductive potential with suspected hypersensitivity to the ingredients in PHEXX. The most common adverse reactions (≥10%) in the U.S. population in Studies 1 and 2 (n=2480) were: vulvovaginal burning sensation (18.0%) and vulvovaginal pruritus (14.5%). The majority of these adverse reactions were mild and few led to discontinuation. Table 1 summarizes the most common adverse reactions (≥2%) reported by subjects using PHEXX in the U.S. Table 1. Adverse Reactions that Occurred in ≥2% of Subjects Who Used PHEXX to Prevent Pregnancy (Studies 1 and 2 – U.S. population only) Adverse Reaction PHEXX (N=2480) (%) Vulvovaginal Burning Sensation 18.0 Vulvovaginal Pruritus 14.5 Vulvovaginal Mycotic Infection Includes preferred terms (PT) vulvovaginal mycotic infection and vulvovaginal candidiasis. 9.1 Urinary Tract Infection Includes PTs urinary tract infection, streptococcal urinary tract infection, Escherichia urinary tract infection, and urinary tract infection bacterial. Does not include PTs cystitis, kidney infection, and pyelonephritis [see Warnings and Precautions (5.1)]. 9.0 Vulvovaginal Discomfort 9.0 Bacterial Vaginosis 8.4 Vaginal Discharge 5.5 Genital Discomfort 4.1 Dysuria 3.1 Vulvovaginal Pain 2.1 Among subjects who used PHEXX in Studies 1 and 2, 1.6% discontinued from the clinical trials due to an adverse reaction. The most common adverse reactions leading to study discontinuation were vulvovaginal burning sensation (0.7%); and vulvovaginal pruritus and vulvovaginal discomfort (0.1% each).
Table from the label
| Adverse Reaction | PHEXX (N=2480) (%) |
|---|---|
| Vulvovaginal Burning Sensation | 18.0 |
| Vulvovaginal Pruritus | 14.5 |
| Vulvovaginal Mycotic InfectionIncludes preferred terms (PT) vulvovaginal mycotic infection and vulvovaginal candidiasis. | 9.1 |
| Urinary Tract InfectionIncludes PTs urinary tract infection, streptococcal urinary tract infection, Escherichia urinary tract infection, and urinary tract infection bacterial.Does not include PTs cystitis, kidney infection, and pyelonephritis [see Warnings and Precautions (5.1)]. | 9.0 |
| Vulvovaginal Discomfort | 9.0 |
| Bacterial Vaginosis | 8.4 |
| Vaginal Discharge | 5.5 |
| Genital Discomfort | 4.1 |
| Dysuria | 3.1 |
| Vulvovaginal Pain | 2.1 |
— FDA label: Phexx, Evofem, Inc., effective May 2, 2025. This is part of the section. Read the full label on DailyMed →
Lactic acid, l-, citric acid monohydrate, and potassium bitartrate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Administer one (1) pre-filled single-dose applicator of PHEXX (5 grams) vaginally immediately before (or up to one hour before) each episode of vaginal intercourse (2.1) May use during any part of the menstrual cycle (2.2) 2.1 Recommended Dosage Administer one pre-filled applicator of PHEXX (5 grams) vaginally immediately before or up to one hour before each act of vaginal intercourse.
Read more of this section
If more than one act of vaginal intercourse occurs within one hour, an additional dose must be applied. Five grams of PHEXX contains 90 mg of lactic acid, 50 mg of citric acid, and 20 mg of potassium bitartrate. 2.2 Timing of PHEXX Use May use PHEXX during any part of the menstrual cycle. May use PHEXX as soon as it is safe to resume vaginal intercourse after childbirth, abortion, or miscarriage. 2.3 Use of PHEXX with Other Contraceptive Methods PHEXX may be used concomitantly with hormonal contraceptives; latex, polyurethane, and polyisoprene condoms; and vaginal diaphragms. Avoid PHEXX use with vaginal rings. 2.4 Use of PHEXX with Other Vaginal Products PHEXX may be used concomitantly with other products for vaginal infections including miconazole, metronidazole, and tioconazole.
— FDA label: Phexx, Evofem, Inc., effective May 2, 2025. Read the full label on DailyMed →
Lactic acid, l-, citric acid monohydrate, and potassium bitartrate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary There is no use for PHEXX in pregnancy; therefore, discontinue PHEXX during pregnancy. There are no data with the use of PHEXX in pregnant women or animals. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.
— FDA label: Phexx, Evofem, Inc., effective May 2, 2025. Read the full label on DailyMed →
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| citric acid monohydrate 50 mg/5 g · lactic acid, l- 90 mg/5 g · potassium bitartrate 20 mg/5 g gel | Brand: Phexx | $6.06 per gram |
| citric acid monohydrate 50 mg/5 g · lactic acid, l- 90 mg/5 g · potassium bitartrate 20 mg/5 g gel | Brand: Phexxi | $6.06 per gram |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Evofem, Inc.2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA208352 PHEXX | Evofem Inc | May 22, 2020 | 2, latest April 21, 2025 2025: Labeling · 2022: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2385348, 2385353, 2700386 |
|---|---|
| SPL set ID of the quoted label | 14b01a15-9b47-4be3-bb2e-a2010eab429e |
| FDA labels (SPL) | 2 |
| FDA applications | NDA208352 |
| Active ingredients (FDA) | CITRIC ACID MONOHYDRATE / LACTIC ACID, L- / POTASSIUM BITARTRATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- PhexxBrand page: products, maker and price
- PhexxiBrand page: products, maker and price
- Evofem, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Phexx, Evofem, Inc., effective May 2, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →